3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Ovarian Neoplasms
92
Fallopian Tube Neoplasms
25
Breast Neoplasms
21
Endometrial Neoplasms
19
Carcinoma, Ovarian Epithelial
12
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Neoplasms
6
Fanconi Anemia, Complementation Group D1
5
Uterine Cervical Neoplasms
4
Recurrence
4
Neoplasm Metastasis
4
Carcinoma, Renal Cell
3
Uterine Neoplasms
2
Stomach Neoplasms
2
Peritoneal Neoplasms
2
Ovarian Diseases
2
Carcinosarcoma
2
Carcinoma, Non-Small-Cell Lung
2
Urogenital Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Relapsed Ovarian Cancers Patients
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Platinum-sensitive Ovarian Cancer
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Interventions
pembrolizumab
5
Magnetic Resonance Spectroscopy
4
Trastuzumab
3
Nivolumab
3
ulixertinib
2
palbociclib
2
lenvatinib
2
belinostat
2
Sunitinib
2
Specimen Handling
2
Fluorodeoxyglucose F18
2
FAPI-46
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tislelizumab
1
tipifarnib
1
spartalizumab
1
sargramostim
1
sapanisertib
1
relatlimab
1
pertuzumab
1
pazopanib
1
osimertinib
1
omipalisib
1
olaparib
1
methyl N-acetylsibirosaminide
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
olaparib
×
Gynecologic
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled